The pulp and paper industry throws away millions of tons of Kraft black liquor every year. It is dark, foul-smelling, and toxic. A team of Brazilian and American researchers has figured out how to turn it into a scaffold that helps broken bones heal. Nature Scientific Reports
In rats, a carbon-graphene scaffold made from this industrial waste achieved roughly 90 percent bone repair in tibia defects within 30 days, according to a peer-reviewed study published in Nature Scientific Reports. The work is still at the animal-study stage, and human trials are not imminent. But the material is cheap to produce, degrades at the right pace inside the body, and appears to recruit the bone cells the body already uses for repair. That combination is harder to achieve than it sounds, and it is why the researchers think they have something worth pursuing.
The clinical problem they are trying to solve is real. Children born with cleft lip and palate often need alveolar bone repair before their adult teeth can erupt properly. The current standard involves a scaffold made from collagen and hydroxyapatite, a ceramic putty that holds its shape long enough for new bone to form. It works, but it degrades too slowly. In a multicenter clinical study using that material, canine tooth impaction occurred in 30 percent of cases. Nature Scientific Reports When a tooth cannot erupt because the scaffold is still in the way, the patient needs orthodontic traction, more surgery, and more time in treatment. The researchers write that this motivated the search for a material that degrades faster while still giving new bone enough time to form.
The new scaffold, called CANG (carbon associated with nanographite), is made by combining carbon derived from Kraft black liquor with nanographite particles and a chitosan-xanthan polymer matrix. Nature Scientific Reports The nanographite is added at 0.1 percent by weight; the graphene derivatives are provided by the MG-graphene Project. Nature Scientific Reports
What the carbon-graphene combination does, the researchers argue, is give bone-forming cells a surface they want to colonize. In cell viability tests using human bone marrow-derived mesenchymal stem cells from a line purchased from Applied Biological Materials, the CANG scaffold promoted cell attachment and proliferation over seven days. The in vivo results in rats are the headline number: nearly 90 percent repair of the defect area at 30 days. By comparison, scaffolds made from pure carbon or graphene oxide performed worse. The nanographene version hit the sweet spot of surface chemistry and degradation rate.
The study is a collaboration between the LM2C2 research group at the University of São Paulo, Sírio-Libanês Hospital in São Paulo, the Regenerative Bioengineering and Repair Laboratory at UCLA's David Geffen School of Medicine, and R-Crio Company. Nature Scientific Reports FAPESP, the São Paulo state research funding agency, supported the work through grant 2020/12954-2. Genesis Publications R-Crio fabricated the scaffolds at its laboratory in Campinas. Nature Scientific Reports
Daniela Franco Bueno, lead author of the study and a researcher at Albert Einstein Israeli Faculty of Health Sciences in São Paulo, said in an interview with Phys.org that the technology is at an advanced stage of preclinical development with a clear path toward clinical trials. Phys.org She did not give a timeline.
The path forward is standard for a biomaterial moving toward human use: larger animal studies to confirm safety and efficacy, regulatory filings (the Brazilian health regulatory agency ANVISA would need to approve an Investigational Device Exemption for a first-in-human study), then a pilot trial in cleft lip and palate patients. That sequence takes years, assuming the data holds. Biomaterials that look promising in rats routinely fail in larger animals or humans for reasons that are difficult to predict from small-animal studies.
What makes the CANG scaffold worth watching is the combination of low cost, appropriate degradation kinetics, and the bone-cell recruitment signal in the rat data. If those properties hold up in a pig or goat model, the commercial case becomes plausible. A scaffold that degrades when it should, recruits the right cells, and costs less than the collagen-hydroxyapatite alternative would be attractive in any health system that treats cleft lip and palate, which is most of them. The global burden falls disproportionately on low- and middle-income countries where the surgery is already delayed by cost and infrastructure.
Whether CANG gets there depends on the next animal study and whether the degradation rate, which looked right in rats, proves consistent in larger animals with bone physiology closer to humans. The researchers have a hypothesis about why it works: the carbon surface chemistry, particularly in the nanographene formulation, promotes the localized bone response without needing added growth factors or stem cells. That would simplify manufacturing and reduce cost. But it is still a hypothesis backed by one rat study.
The paper does not claim the scaffold is ready for patients. The lead author comes closer to that framing in a press interview than the paper itself does. That is worth noting: the press account is slightly ahead of the data, which is a familiar pattern in biomedical research coverage. The actual state of knowledge is a 30-day rat result, a plausible mechanism, and a research group with a plan. It is not a clinical trial. It is not a product. It is a material that does what the researchers hoped it would do in an animal that cannot consent to the coverage.
Notebook: Kraft black liquor has been a disposal problem for pulp mills for over a century. It is early, but if this material makes it to patients, the waste stream becomes part of the supply chain. That is a different story from "graphene heals bones," and it is the one worth following.
